CARBAPENEM-RESISTANT PATTERN OF ENTEROBACTERIACEAE AT NGUYEN TRI PHUONG HOSPITAL DURING THE PERIOD 2019-2023

Hữu Ngọc Tuấn Nguyễn, Quang Huy Nguyễn, Minh Hà Nguyễn

Main Article Content

Abstract

Background: Carbapenem-resistant Enterobacteriaceae is complicated. It is need for a comprehensive management strategy and rational use of these antibiotics to enhance the effectiveness of infection treatment. Objective: To determine the prevalence and the Carbapenem - resistant pattern of Enterobacteriaceae from 2019 to 2022. Subjects and methods: Antibiotic resistance data of bacterial strains of the Enterobacteriaceae family isolated from patients undergoing treatment at Nguyen Tri Phuong Hospital from January 2019 to December 2023, with results specifically focusing on Carbapenem antibiotic resistance. Differences in antibiotic susceptibility trends over the years were investigated using the Chi-square test. Results: During the period 2019-2023, a total of 11,591 cultures were isolated from bacteria belonging to the Enterobacteriaceae family. The highest proportions were E.coli (16.7%), K.pneumoniae (12.8%), Enterobacter spp (3.6%), and other Enterobacteriaceae bacteria (4.2%). Respiratory specimens, pus/secretion/catheter samples, urine, and blood were the types of specimens with high rates of positive cultures for Enterobacteriaceae bacteria. K.pneumoniae exhibited the highest Carbapenem resistance rate (29.6%), followed by Enterobacter spp (10.2%), Enterobacteriaceae bacteria (4.0%), and E.coli (3.6%). There was an observed increasing trend in resistance to Amoxicillin-Clavulanate, Cefoxitin, and Imipenem in both E.coli and K.pneumoniae (p<0.001). The Carbapenem resistance rate in the Intensive Care Unit (ICU) was higher than in other clinical departments for all Enterobacteriaceae bacteria surveyed (p<0.001). Strains exhibiting Carbapenem resistance, producing ESBL and/or AmpC enzymes, had a lower prevalence compared to non-producing strains. Conclusions: Enterobacteriaceae exhibit a high rate of resistance and a increasing trend towards resistance to the Carbapenem group, especially K.pneumoniae. Therefore, a prudent strategy for the management and rational use of this antibiotic group is essential.

Article Details

References

1. Davies, O. and S. Bennett, WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO Newsletters, 2017.
2. Vân, P.T., P.V. Hậu, N.T. Giang, and Đ.T.T. Hà, Tính kháng kháng sinh của các chủng vi khuẩn Enterobacteriaceae phân lập tại bệnh viện E (2018-2020). Tạp chí Truyền nhiễm Việt Nam, 2023. 1(41): p. 67-73.
3. Tilahun, M., Y. Kassa, A. Gedefie, and M. Ashagire, Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infection and Drug Resistance, 2021: p. 4363-4374.
4. Lương, T.H.N., A. Hoang, T.K.H. Trần, and X.Q. Nghiêm, Đặc điểm kháng kháng sinh của một số vi khuẩn Gram âm sinh enzyme beta lactamase phổ rộng phân lập tại bệnh viện Trung ương Thái Nguyên năm 2018-2020. Tạp chí Y học Việt Nam, 2022. 512(2).
5. Thomas, M.G. and S.J. Streat, CHAPTER 41 - Infections in intensive care patients, in Antibiotic and Chemotherapy (Ninth Edition), R.G. Finch, D. Greenwood, S.R. Norrby, and R.J. Whitley, Editors. 2010, W.B. Saunders: London. p. 524-537.
6. Mol, P.R., K.M. Bindayna, and G. Shanthi, Evaluation of Two Phenotypic Methods for the Detection of Plasmid-Mediated AmpC β-Lactamases among Enterobacteriaceae Isolates. J Lab Physicians, 2021. 13(2): p. 151-155.
7. Phu, V.D., et al., Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units. PloS one, 2016. 11(1): p. e0147544.
8. Parker, J.K., et al., Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas. Infect Drug Resist, 2023. 16: p. 1249-1261.
9. Gupta, G., V. Tak, and P. Mathur, Detection of AmpC β Lactamases in Gram-negative Bacteria. J Lab Physicians, 2014. 6(1): p. 1-6.